fluoxetine has been researched along with Substance Withdrawal Syndrome in 97 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nineteen mentally retarded inpatients with epilepsy and a history of current or recent aggressive behavior were treated with 20 mg of fluoxetine daily." | 9.08 | Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. ( Ciani, N; Nuccetelli, F; Pasini, A; Troisi, A; Vicario, E, 1995) |
| "Discontinuation syndrome is associated with a rostral anterior cingulate Cho/Cre metabolite ratio decrease that may reflect dynamics of rostral anterior cingulate function." | 6.71 | Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. ( Cohen, BM; Frederick, Bd; Hennen, J; Henry, ME; Kaufman, MJ; Renshaw, PF; Schmidt, ME; Stoddard, EP; Villafuerte, RA, 2003) |
| "Recent studies have shown that withdrawal symptoms are common with paroxetine, venlafaxine and fluvoxamine, but relatively rare and mild with fluoxetine cessation, likely as a result of its longer half-life." | 5.35 | Delirium following abrupt discontinuation of fluoxetine. ( Blum, D; Lansberg, M; Maldonado, J; Meyer, E, 2008) |
| "The authors randomly assigned nondepressed patients at least 3 months poststroke to receive nortriptyline, fluoxetine, or placebo for 3 months using double-blind methodology." | 5.12 | Risk factors for and correlates of poststroke depression following discontinuation of antidepressants. ( Fiedorowicz, JG; Robinson, RG; Takezawa, K, 2007) |
| "A discontinuation syndrome is common after treatment with SSRIs is stopped in patients with dysthymia, and it appears to be more common in patients receiving paroxetine than in those receiving fluoxetine." | 5.10 | Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. ( Bellino, S; Bogetto, F; Patria, L; Revello, RB, 2002) |
| "Nineteen mentally retarded inpatients with epilepsy and a history of current or recent aggressive behavior were treated with 20 mg of fluoxetine daily." | 5.08 | Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. ( Ciani, N; Nuccetelli, F; Pasini, A; Troisi, A; Vicario, E, 1995) |
| "Nondepressed participants (N = 114) in a trial investigating the effect of fluoxetine on smoking cessation were administered the Structured Clinical Interview for DSM-III-R at baseline and posttreatment to evaluate the impact of quitting smoking on the development of MDD." | 5.08 | Development of major depressive disorder during smoking-cessation treatment. ( Abrams, DB; Borrelli, B; DePue, JD; Goldstein, MG; Keuthen, NJ; Murphy, C; Niaura, R, 1996) |
| "A group of 23 elderly outpatients with dysthymic disorder participated in a 13-week fluoxetine trial." | 5.08 | Fluoxetine discontinuation in elderly dysthymic patients. ( Devanand, DP; Kim, MK; Nobler, MS, 1997) |
| "Suicidality data from 11 double-blind controlled trials in the United States Investigational New Drug fluoxetine obesity clinical trial data base (3819 randomized outpatients) were reviewed." | 5.07 | Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. ( Beasley, CM; Goldstein, DJ; Masica, DN; Potvin, JH; Rampey, AH, 1993) |
| "Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders." | 4.82 | Safety and side effect profile of fluoxetine. ( Wernicke, JF, 2004) |
| "The suitability of the zebrafish model of anhedonia using reserpine and fluoxetine was evaluated." | 4.31 | Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase. ( Braida, D; Dellarole, I; Morara, S; Ponzoni, L; Sala, M, 2023) |
| " twice daily for 9 days) suppressed the development of morphine dependence as assessed by naloxone (2 mg/kg i." | 3.72 | Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways. ( Jain, NK; Kulkarni, SK; Singh, VP, 2003) |
| "The symptom of "diminished interest or pleasure" in rewarding stimuli is an affective symptom of nicotine and amphetamine withdrawal, and a core symptom of depression." | 3.71 | Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. ( Harrison, AA; Liem, YT; Markou, A, 2001) |
| "Discontinuation syndrome is associated with a rostral anterior cingulate Cho/Cre metabolite ratio decrease that may reflect dynamics of rostral anterior cingulate function." | 2.71 | Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. ( Cohen, BM; Frederick, Bd; Hennen, J; Henry, ME; Kaufman, MJ; Renshaw, PF; Schmidt, ME; Stoddard, EP; Villafuerte, RA, 2003) |
| "The paroxetine treatment group also experienced significant increases in depressive symptoms, clinical global severity scores and difficulty in social functioning; the fluoxetine treatment group did not." | 2.70 | Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. ( Jacobson, JG; Judge, R; Parry, MG; Quail, D, 2002) |
| " However, the time course for maximum inhibition to occur or for inhibition to dissipate when dosing is discontinued, requires clarification." | 2.70 | Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. ( Boulton, DW; DeVane, CL; Goldman, J; Liston, HL; Markowitz, JS; Risch, SC, 2002) |
| "Mild, self-limited lightheadedness or dizziness occurred in a small percentage of patients who discontinued fluoxetine treatment but was of little clinical significance." | 2.69 | Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. ( Amsterdam, J; Beasley, C; Fawcett, J; Michelson, D; Quitkin, F; Reimherr, F; Rosenbaum, J; Zajecka, J, 1998) |
| "Fluoxetine-treated patients also experienced less reemergence of depressive symptoms than sertraline-treated or paroxetine-treated patients (p < ." | 2.69 | Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. ( Ascroft, RC; Fava, M; Hoog, SL; Krebs, WB; Rosenbaum, JF, 1998) |
| " Mild symptoms can often be treated by simply reassuring the patient that they are usually transient, but for more severe symptoms, it may be necessary to reinstitute the dosage of the original antidepressant and slow the rate of taper." | 2.40 | Clinical management of antidepressant discontinuation. ( Rosenbaum, JF; Zajecka, J, 1997) |
| "Recent studies have shown that withdrawal symptoms are common with paroxetine, venlafaxine and fluvoxamine, but relatively rare and mild with fluoxetine cessation, likely as a result of its longer half-life." | 1.35 | Delirium following abrupt discontinuation of fluoxetine. ( Blum, D; Lansberg, M; Maldonado, J; Meyer, E, 2008) |
| "The most common withdrawal symptoms among those with cannabis dependence were craving (82%), irritability (76%), restlessness (58%), anxiety (55%), and depression (52%)." | 1.35 | Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. ( Chung, T; Clark, DB; Cornelius, JR; Martin, C; Wood, DS, 2008) |
| " In conclusion, ethanol-withdrawal on chronic administration increases marble-burying behavior in mice; its development and expression is attenuated by leuprolide." | 1.35 | Increased marble-burying behavior in ethanol-withdrawal state: modulation by gonadotropin-releasing hormone agonist. ( Bhutada, P; Dixit, P; Shende, V; Umathe, S, 2008) |
| "Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats." | 1.33 | Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. ( Cador, M; Koob, GF; Stinus, L; Zorrilla, EP, 2005) |
| " Our hypothesis was that subchronic intake should cause changes qualitatively different from the single dose and that such changes could be sufficiently long-lived to suggest the possibility of a dosing in intervals of several days." | 1.31 | Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. ( Berger, M; Dittmann, R; Feige, B; Hohagen, F; Riemann, D; Voderholzer, U, 2002) |
| "Fluoxetine (alone) treatment of rats for 1 or 15 days had no effect on open-arm activity and cortical CRE-DNA-binding activity." | 1.30 | Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety. ( Mittal, N; Nayyar, D; Pandey, SC; Zhang, D, 1999) |
| " Nevertheless, the effects of long-term administration and withdrawal from other drugs, such as fluoxetine, that have the potential to elevate mood in depressed individuals have not been characterized." | 1.30 | Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat--interactions between the two drugs. ( Koob, GF; Lin, D; Markou, A, 1999) |
| "Withdrawal symptoms were diverse but most commonly comprised dizziness, paraesthesia, tremor, anxiety, nausea and palpitation." | 1.29 | A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. ( MacKay, AV; Price, JS; Waller, PC; Wood, SM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (4.12) | 18.7374 |
| 1990's | 43 (44.33) | 18.2507 |
| 2000's | 35 (36.08) | 29.6817 |
| 2010's | 11 (11.34) | 24.3611 |
| 2020's | 4 (4.12) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, C | 1 |
| Braida, D | 1 |
| Ponzoni, L | 1 |
| Dellarole, I | 1 |
| Morara, S | 1 |
| Sala, M | 1 |
| Dolatshahi, M | 1 |
| Davoudi, S | 1 |
| Paridar, Y | 1 |
| Naserzadeh, R | 1 |
| Ghorbanzadeh, B | 1 |
| Abou Kassm, S | 1 |
| Naja, W | 1 |
| Henssler, J | 1 |
| Heinz, A | 1 |
| Brandt, L | 1 |
| Bschor, T | 1 |
| Suárez, J | 1 |
| Khom, S | 1 |
| Alén, F | 1 |
| Natividad, LA | 1 |
| Varodayan, FP | 1 |
| Patel, RR | 1 |
| Kirson, D | 1 |
| Arco, R | 1 |
| Ballesta, A | 1 |
| Bajo, M | 1 |
| Rubio, L | 1 |
| Martin-Fardon, R | 1 |
| Rodríguez de Fonseca, F | 1 |
| Roberto, M | 1 |
| Özcan, Ö | 1 |
| Özdemir, S | 1 |
| Kütük, ÖM | 1 |
| Cheaha, D | 2 |
| Sawangjaroen, K | 2 |
| Kumarnsit, E | 2 |
| Pittman, JT | 1 |
| Lott, CS | 1 |
| Lutz, PE | 2 |
| Ayranci, G | 1 |
| Chu-Sin-Chung, P | 1 |
| Matifas, A | 1 |
| Koebel, P | 1 |
| Filliol, D | 1 |
| Befort, K | 1 |
| Ouagazzal, AM | 2 |
| Kieffer, BL | 2 |
| Philip, NS | 1 |
| Minami, H | 1 |
| Kahler, CW | 1 |
| Bloom, EL | 1 |
| Prince, MA | 1 |
| Abrantes, AM | 1 |
| Strong, DR | 1 |
| Niaura, R | 2 |
| Miller, IW | 1 |
| Palm Reed, KM | 1 |
| Price, LH | 1 |
| Brown, RA | 1 |
| Keawpradub, N | 1 |
| Phukpattaranont, P | 1 |
| Nanchen, D | 1 |
| Willi, C | 1 |
| Peytremann-Bridevaux, I | 1 |
| Burnand, B | 1 |
| Walther, MR | 1 |
| Velez, LI | 1 |
| Feng, SY | 1 |
| Neerman, MF | 1 |
| Goeldner, C | 1 |
| Darcq, E | 1 |
| Halter, T | 1 |
| Clesse, D | 1 |
| Judge, R | 1 |
| Parry, MG | 1 |
| Quail, D | 1 |
| Jacobson, JG | 1 |
| Romeo, E | 1 |
| Pompili, E | 1 |
| di Michele, F | 1 |
| Pace, M | 1 |
| Rupprecht, R | 1 |
| Bernardi, G | 1 |
| Pasinib, A | 1 |
| Singh, VP | 1 |
| Jain, NK | 1 |
| Kulkarni, SK | 1 |
| Kaufman, MJ | 1 |
| Henry, ME | 1 |
| Frederick, Bd | 1 |
| Hennen, J | 1 |
| Villafuerte, RA | 1 |
| Stoddard, EP | 1 |
| Schmidt, ME | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Stinus, L | 1 |
| Cador, M | 1 |
| Zorrilla, EP | 1 |
| Koob, GF | 2 |
| Wernicke, JF | 1 |
| Martijena, ID | 2 |
| Bustos, SG | 2 |
| Bertotto, ME | 1 |
| Molina, VA | 2 |
| Harris, DS | 1 |
| Batki, SL | 1 |
| Berger, SP | 1 |
| Wu, CC | 1 |
| Chen, JY | 1 |
| Tao, PL | 1 |
| Chen, YA | 1 |
| Yeh, GC | 1 |
| van Geffen, EC | 1 |
| Hugtenburg, JG | 1 |
| Heerdink, ER | 1 |
| van Hulten, RP | 1 |
| Egberts, AC | 1 |
| Poryazova, R | 1 |
| Siccoli, M | 1 |
| Werth, E | 1 |
| Bassetti, CL | 1 |
| Lavenstein, B | 1 |
| Alvarez-Miezentseva, V | 1 |
| Sitges-Serra, A | 1 |
| Krupitsky, EM | 1 |
| Zvartau, EE | 1 |
| Masalov, DV | 1 |
| Tsoy, MV | 1 |
| Burakov, AM | 1 |
| Egorova, VY | 1 |
| Didenko, TY | 1 |
| Romanova, TN | 1 |
| Ivanova, EB | 1 |
| Bespalov, AY | 1 |
| Verbitskaya, EV | 1 |
| Neznanov, NG | 1 |
| Grinenko, AY | 1 |
| O'Brien, CP | 1 |
| Woody, GE | 1 |
| Blum, D | 1 |
| Maldonado, J | 1 |
| Meyer, E | 1 |
| Lansberg, M | 1 |
| Spindler, PE | 1 |
| Fiedorowicz, JG | 1 |
| Takezawa, K | 1 |
| Robinson, RG | 2 |
| Benazzi, F | 6 |
| Cornelius, JR | 1 |
| Chung, T | 1 |
| Martin, C | 1 |
| Wood, DS | 1 |
| Clark, DB | 1 |
| Kwon, P | 1 |
| Lefkowitz, W | 1 |
| Umathe, S | 1 |
| Bhutada, P | 1 |
| Dixit, P | 1 |
| Shende, V | 1 |
| Verberne, AJ | 1 |
| Taylor, DA | 1 |
| Fennessy, MR | 1 |
| Covi, L | 1 |
| Hess, JM | 1 |
| Kreiter, NA | 1 |
| Haertzen, CA | 1 |
| Troisi, A | 1 |
| Vicario, E | 1 |
| Nuccetelli, F | 1 |
| Ciani, N | 1 |
| Pasini, A | 1 |
| Einbinder, E | 1 |
| Hastier, P | 1 |
| Paolini, O | 1 |
| Demarquay, JF | 1 |
| Caroli-Bosc, FX | 1 |
| Chichmanian, RM | 1 |
| Saint-Paul, MC | 1 |
| Delmont, J | 1 |
| Kreider, MS | 1 |
| Bushnell, WD | 1 |
| Oakes, R | 1 |
| Wheadon, DE | 1 |
| Altshuler, LL | 1 |
| Goldstein, DJ | 1 |
| Rampey, AH | 1 |
| Potvin, JH | 1 |
| Masica, DN | 1 |
| Beasley, CM | 2 |
| Connor, DF | 1 |
| Benjamin, S | 1 |
| Ozbayrak, KR | 1 |
| Berlin, CS | 1 |
| Janiri, L | 1 |
| Gobbi, G | 1 |
| Mannelli, P | 1 |
| Pozzi, G | 1 |
| Serretti, A | 1 |
| Tempesta, E | 1 |
| Belej, T | 1 |
| Manji, D | 1 |
| Sioutis, S | 1 |
| Barros, HM | 1 |
| Nobrega, JN | 1 |
| Borrelli, B | 1 |
| Keuthen, NJ | 1 |
| Goldstein, MG | 1 |
| DePue, JD | 1 |
| Murphy, C | 1 |
| Abrams, DB | 1 |
| Price, JS | 1 |
| Waller, PC | 1 |
| Wood, SM | 1 |
| MacKay, AV | 1 |
| Young, AH | 1 |
| Ashton, CH | 1 |
| Devanand, DP | 1 |
| Kim, MK | 1 |
| Nobler, MS | 1 |
| Lejoyeux, M | 1 |
| Adès, J | 1 |
| Haddad, P | 1 |
| Rosenbaum, JF | 3 |
| Zajecka, J | 3 |
| Tracy, KA | 1 |
| Mitchell, S | 1 |
| Stahl, MM | 1 |
| Lindquist, M | 1 |
| Pettersson, M | 1 |
| Edwards, IR | 1 |
| Sanderson, JH | 1 |
| Taylor, NF | 1 |
| Fletcher, AP | 1 |
| Schou, JS | 1 |
| Corá-Locatelli, G | 1 |
| Greenberg, BD | 1 |
| Martin, JD | 1 |
| Murphy, DL | 1 |
| Fawcett, J | 2 |
| Amsterdam, J | 3 |
| Quitkin, F | 1 |
| Reimherr, F | 1 |
| Rosenbaum, J | 1 |
| Michelson, D | 3 |
| Beasley, C | 1 |
| Bjork, JM | 1 |
| Gaytan, O | 1 |
| Patt, N | 1 |
| Swann, AC | 1 |
| Dafny, N | 1 |
| Fava, M | 3 |
| Hoog, SL | 1 |
| Ascroft, RC | 1 |
| Krebs, WB | 1 |
| Pollock, BG | 1 |
| Thompson, C | 1 |
| Raap, DK | 1 |
| Garcia, F | 1 |
| Muma, NA | 1 |
| Wolf, WA | 1 |
| Battaglia, G | 1 |
| van de Kar, LD | 1 |
| Pandey, SC | 1 |
| Zhang, D | 1 |
| Mittal, N | 1 |
| Nayyar, D | 1 |
| Lacerra, C | 1 |
| Lu, ML | 1 |
| Lane, HY | 1 |
| Chang, WH | 1 |
| Lin, D | 1 |
| Markou, A | 2 |
| Shad, MU | 1 |
| Preskorn, SH | 1 |
| Apter, J | 2 |
| Londborg, P | 2 |
| Tamura, R | 2 |
| Pagh, L | 1 |
| Tepner, RG | 1 |
| Wade, GS | 1 |
| Rasmussen, K | 1 |
| Calligaro, DO | 1 |
| Czachura, JF | 1 |
| Dreshfield-Ahmad, LJ | 1 |
| Evans, DC | 1 |
| Hemrick-Luecke, SK | 1 |
| Kallman, MJ | 1 |
| Kendrick, WT | 1 |
| Leander, JD | 1 |
| Nelson, DL | 1 |
| Overshiner, CD | 1 |
| Wainscott, DB | 1 |
| Wolff, MC | 1 |
| Wong, DT | 1 |
| Branchek, TA | 1 |
| Zgombick, JM | 1 |
| Xu, YC | 1 |
| Montero Pérez, FJ | 1 |
| Harris, GC | 1 |
| Aston-Jones, G | 1 |
| Harrison, AA | 1 |
| Liem, YT | 1 |
| Calil, HM | 1 |
| Brunswick, DJ | 1 |
| Amsterdam, JD | 1 |
| Quitkin, FM | 1 |
| Reimherr, FW | 1 |
| Feige, B | 1 |
| Voderholzer, U | 1 |
| Riemann, D | 1 |
| Dittmann, R | 1 |
| Hohagen, F | 1 |
| Berger, M | 1 |
| Liston, HL | 1 |
| DeVane, CL | 1 |
| Boulton, DW | 1 |
| Risch, SC | 1 |
| Markowitz, JS | 1 |
| Goldman, J | 1 |
| Bogetto, F | 1 |
| Bellino, S | 1 |
| Revello, RB | 1 |
| Patria, L | 1 |
| Narushima, K | 1 |
| Kosier, JT | 1 |
| Malone, DA | 1 |
| Dimeff, RJ | 1 |
| McGuirk, J | 1 |
| Muscat, R | 1 |
| Willner, P | 1 |
| Van Ameringen, M | 1 |
| Mancini, C | 1 |
| Nelson, JC | 1 |
| Stoukides, JA | 1 |
| Stoukides, CA | 1 |
| Matthews, P | 1 |
| Quinn, D | 1 |
| Marcoux, GS | 1 |
| Falkenberg, K | 1 |
| Kleven, MS | 1 |
| Sparber, SB | 1 |
| Sternbach, H | 1 |
| Graham, PM | 1 |
| Ilett, KF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for fluoxetine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Antidepressant Withdrawal and Rebound Phenomena.
Topics: Antidepressive Agents; Fluoxetine; Humans; Paroxetine; Retrospective Studies; Selective Serotonin Re | 2019 |
Safety and side effect profile of fluoxetine.
Topics: Adolescent; Adult; Biotransformation; Bipolar Disorder; Cardiovascular Diseases; Child; Comorbidity; | 2004 |
Antidepressant discontinuation: a review of the literature.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Fluoxet | 1997 |
Newer antidepressants and the discontinuation syndrome.
Topics: Adverse Drug Reaction Reporting Systems; Cyclohexanols; Dizziness; Fluoxetine; Headache; Humans; Inc | 1997 |
Clinical management of antidepressant discontinuation.
Topics: Antidepressive Agents; Depressive Disorder; Drug Administration Schedule; Fluoxetine; Half-Life; Hum | 1997 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Femal | 1997 |
Fluoxetine: a suitable long-term treatment.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Tricyclic; Chemistry, Pharmaceutical; Child; Chi | 2001 |
20 trials available for fluoxetine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; F | 2002 |
Effects of fluoxetine, indomethacine and placebo on 3 alpha, 5 alpha tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal.
Topics: Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethanol; F | 2000 |
Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study.
Topics: Adult; Brain Mapping; Choline; Depressive Disorder, Major; Female; Fluoxetine; Gyrus Cinguli; Humans | 2003 |
Fluoxetine attenuates adrenocortical but not subjective responses to cocaine cues.
Topics: Adult; Arousal; Cocaine-Related Disorders; Cues; Double-Blind Method; Female; Fluoxetine; Humans; Hy | 2004 |
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Double-Blind Method; Dru | 2006 |
Risk factors for and correlates of poststroke depression following discontinuation of antidepressants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Gen | 2007 |
Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Cocaine; Combined Modality Therapy | 1995 |
Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy.
Topics: Adult; Aggression; Epilepsy; Female; Fluoxetine; Humans; Individuality; Intellectual Disability; Mal | 1995 |
A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period.
Topics: Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; H | 1995 |
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Benzphetamine; Body Mass Index; Comorbidity; Depressive Di | 1993 |
Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics.
Topics: Adult; Alcoholism; Double-Blind Method; Ethanol; Female; Fluoxetine; Humans; Italy; Male; Middle Age | 1996 |
Development of major depressive disorder during smoking-cessation treatment.
Topics: Behavior Therapy; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Male; Middle Aged; P | 1996 |
Fluoxetine discontinuation in elderly dysthymic patients.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Dose-Response Relationship, | 1997 |
Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dizziness; Double-Blind Method | 1998 |
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Topics: 1-Naphthylamine; Adult; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration S | 1998 |
Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment.
Topics: Adult; Biomarkers; Cross-Over Studies; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; | 2000 |
Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Fluoxetine; Humans; Male; Mental Disorders | 2000 |
Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6 Inhibitors; Female; Fluoxetine; Half-Life; Humans; Male; | 2002 |
Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Dysthymic Disorder; Female; Fluox | 2002 |
Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; | 2002 |
70 other studies available for fluoxetine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Psychotropic Drugs With Long Half-Lives: Implications for Drug Discontinuation, Occasional Missed Doses, Dosing Interval, and Pregnancy Planning.
Topics: Female; Fluoxetine; Half-Life; Humans; Pregnancy; Psychotropic Drugs; Substance Withdrawal Syndrome; | 2022 |
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase.
Topics: Anhedonia; Animals; Calcitonin Gene-Related Peptide; Fluoxetine; Nicotine; Reserpine; Substance With | 2023 |
Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Depression; Drug Tolerance; Fl | 2020 |
Looking for bipolarity in antidepressant discontinuation manic states: Update and diagnostic considerations of the phenomenon.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Child; Citalopram; Cyclothy | 2018 |
Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala.
Topics: Alcoholism; Animals; Central Amygdaloid Nucleus; Disease Models, Animal; Drug-Seeking Behavior; Endo | 2020 |
Manic symptoms as a symptom of antidepressant discontinuation syndrome in a child.
Topics: Antidepressive Agents; Bipolar Disorder; Child; Female; Fluoxetine; Humans; Substance Withdrawal Syn | 2013 |
Characterization of fluoxetine effects on ethanol withdrawal-induced cortical hyperexcitability by EEG spectral power in rats.
Topics: Animals; Cerebral Cortex; Electroencephalography; Ethanol; Fluoxetine; Male; Motor Activity; Rats; R | 2014 |
Startle response memory and hippocampal changes in adult zebrafish pharmacologically-induced to exhibit anxiety/depression-like behaviors.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety; Central Nervous Sy | 2014 |
Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Dorsal Raphe | 2014 |
An aripiprazole discontinuation syndrome.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressiv | 2013 |
Effects of sequential fluoxetine and gender on prequit depressive symptoms, affect, craving, and quit day abstinence in smokers with elevated depressive symptoms: a growth curve modeling approach.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Craving; Depressive Disorder; Fem | 2014 |
Effects of an alkaloid-rich extract from Mitragyna speciosa leaves and fluoxetine on sleep profiles, EEG spectral frequency and ethanol withdrawal symptoms in rats.
Topics: Alkaloids; Animals; Electrodes; Electroencephalography; Ethanol; Fluoxetine; Male; Mitragyna; Plant | 2015 |
[Preventing weight gain in smoking cessation: there is no miracle solution].
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans; | 2009 |
A dispensing error resulting in possible fluoxetine overdose and subsequent discontinuation syndrome in a child.
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Overdose; Fluoxetine; Gastroesophageal Ref | 2010 |
Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine.
Topics: Adrenocorticotropic Hormone; Animals; Corticosterone; Disease Models, Animal; Drug Evaluation, Precl | 2011 |
Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways.
Topics: Animals; Arginine; Body Weight; Cyclic GMP; Depression, Chemical; Diarrhea; Dopamine; Drug Interacti | 2003 |
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Topics: Acamprosate; Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Avoidance Learni | 2005 |
Antidepressants attenuate both the enhanced ethanol intake and ethanol-induced anxiolytic effects in diazepam withdrawn rats.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety | 2005 |
Serotonin reuptake inhibitors attenuate morphine withdrawal syndrome in neonatal rats passively exposed to morphine.
Topics: Animals; Animals, Newborn; Behavior, Animal; Citalopram; Clomipramine; Female; Fluoxetine; Maternal- | 2005 |
Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
Topics: Adult; Citalopram; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Netherlands; Paroxetin | 2005 |
Unusually prolonged rebound cataplexy after withdrawal of fluoxetine.
Topics: Brain Stem; Cataplexy; Electroencephalography; Electromyography; Female; Fluoxetine; Humans; Middle | 2005 |
Neonatal signs after in utero exposure to selective serotonin reuptake inhibitors.
Topics: Female; Fluoxetine; Humans; Infant Behavior; Infant, Newborn; Infant, Newborn, Diseases; Pregnancy; | 2005 |
[Post-parathyroidectomy paresthesiae due to fluoxetin withdrawal].
Topics: Female; Fluoxetine; Humans; Middle Aged; Parathyroidectomy; Paresthesia; Selective Serotonin Reuptak | 2006 |
Delirium following abrupt discontinuation of fluoxetine.
Topics: Delirium; Female; Fluoxetine; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Substanc | 2008 |
[Palinopsia following discontinuation of venlafaxine].
Topics: Adult; Afterimage; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Dos | 2008 |
Fluoxetine for the treatment of SSRI discontinuation syndrome.
Topics: Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2008 |
Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.
Topics: Adolescent; Cannabinoids; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Diagnosti | 2008 |
Poor neonatal adaptation in term infant. Fluoxetine toxicity.
Topics: Depression; Female; Fluoxetine; Humans; Infant, Newborn; Male; Maternal Welfare; Pregnancy; Prenatal | 2008 |
Increased marble-burying behavior in ethanol-withdrawal state: modulation by gonadotropin-releasing hormone agonist.
Topics: Animals; Behavior, Animal; Central Nervous System Depressants; Ethanol; Fluoxetine; Gonadotropin-Rel | 2008 |
Withdrawal-like behaviour induced by inhibitors of biogenic amine reuptake in rats treated chronically with delta 9-tetrahydrocannabinol.
Topics: Animals; Biogenic Amines; Body Weight; Clomipramine; Dronabinol; Eating; Fluoxetine; Humans; Imipram | 1980 |
Fluoxetine withdrawal?
Topics: Depressive Disorder; Dizziness; Female; Fluoxetine; Humans; Substance Withdrawal Syndrome | 1995 |
[Fulminant hepatitis induced by paracetamol at a therapeutic dose favoured by the ingestion of enzyme inducers in a patient with liver cirrhosis].
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Depressive D | 1995 |
Fluoxetine-associated panic attacks.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Humans; Panic; Premenstrual Syndrome; Recurrence; Su | 1994 |
Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment.
Topics: Antipsychotic Agents; Dextroamphetamine; Diphenhydramine; Fluoxetine; Humans; Male; Mental Disorders | 1995 |
Fluoxetine withdrawal symptoms.
Topics: Adult; Anxiety Disorders; Dizziness; Fluoxetine; Humans; Male; Middle Aged; Substance Withdrawal Syn | 1996 |
Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects.
Topics: Administration, Oral; Animals; Autoradiography; Biological Transport; Brain; Carrier Proteins; Cocai | 1996 |
A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Product Surveilla | 1996 |
Pharmacokinetics of fluoxetine.
Topics: Drug Interactions; Fluoxetine; Half-Life; Humans; Selective Serotonin Reuptake Inhibitors; Substance | 1996 |
Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy.
Topics: Adult; Antidepressive Agents; Clonazepam; Cyclohexanols; Depressive Disorder; Desipramine; Drug Ther | 1997 |
Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system.
Topics: 1-Naphthylamine; Adverse Drug Reaction Reporting Systems; Female; Fluoxetine; Humans; Male; Paroxeti | 1997 |
Rebound psychiatric and physical symptoms after gabapentin discontinuation.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fluoxetin | 1998 |
Behavioral tolerance to and withdrawal from multiple fluoxetine administration.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug Tolerance; Fluoxetine; Male; Motor | 1998 |
SSRI discontinuation syndrome treated with fluoxetine.
Topics: Aged; Akathisia, Drug-Induced; Dizziness; Drug Administration Schedule; Female; Fluoxetine; Humans; | 1998 |
Fluoxetine for serotonin reuptake inhibitor discontinuation syndrome.
Topics: Adult; Aged; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Substance Wi | 1998 |
Discontinuation symptoms and SSRIs.
Topics: Biological Availability; Depressive Disorder; Dizziness; Fluoxetine; Follow-Up Studies; Half-Life; H | 1998 |
Discontinuation of antidepressant therapy: emerging complications and their relevance.
Topics: Antidepressive Agents; Depressive Disorder; Fluoxetine; Humans; Paroxetine; Placebos; Randomized Con | 1998 |
Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/z proteins.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenocorticotropic Hormone; Animals; Brain; Drug Interactio | 1999 |
Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety.
Topics: Animals; Anxiety; Central Nervous System Depressants; Cerebral Cortex; Cyclic AMP Response Element-B | 1999 |
Re: Selective serotonin reuptake inhibitor discontinuation syndrome: putative mechanisms and prevention strategies.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Selective | 1999 |
Benzodiazepine withdrawal facilitates the subsequent onset of escape failures and anhedonia: influence of different antidepressant drugs.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Antidepressive Agents; Avoidance Learning; Conditioning, | 1999 |
Fluoxetine for clomipramine withdrawal symptoms.
Topics: Adult; Clomipramine; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Male; Panic Disorder; Sub | 1999 |
Selective serotonin reuptake inhibitor syndrome: precipitated by concomitant clozapine?
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoxe | 1999 |
Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat--interactions between the two drugs.
Topics: Amphetamine; Animals; Brain; Central Nervous System Stimulants; Drug Interactions; Fluoxetine; Male; | 1999 |
Drug-drug interaction in reverse: possible loss of phenytoin efficacy as a result of fluoxetine discontinuation.
Topics: Adult; Anticonvulsants; Drug Interactions; Epilepsy, Tonic-Clonic; Fluoxetine; Humans; Male; Phenyto | 1999 |
Controlled withdrawal for psychotropic drugs.
Topics: Antidepressive Agents, Second-Generation; Fluoxetine; Humans; Psychotropic Drugs; Substance Withdraw | 2000 |
The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Animals; Body Temperature; Columbidae; | 2000 |
[Fluoxetine and convulsive crisis].
Topics: Antidepressive Agents, Second-Generation; Fluoxetine; Humans; Seizures; Selective Serotonin Reuptake | 2000 |
Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal.
Topics: 5-Hydroxytryptophan; Animals; Anxiety; Conditioning, Psychological; Drug Administration Schedule; En | 2001 |
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Topics: Aminopyridines; Amphetamine; Amphetamine-Related Disorders; Animals; Body Weight; Brain; Depression; | 2001 |
Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.
Topics: Depression; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndro | 2001 |
Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects.
Topics: Adult; Algorithms; Antidepressive Agents, Second-Generation; Depression; Dose-Response Relationship, | 2002 |
The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series.
Topics: Adult; Anabolic Agents; Depressive Disorder; Fluoxetine; Humans; Male; Substance Withdrawal Syndrome | 1992 |
Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight and the behavioural satiety sequence.
Topics: Animals; Behavior, Animal; Body Weight; Feeding Behavior; Fenfluramine; Fluoxetine; Grooming; Male; | 1992 |
Adverse effects of switching from fluoxetine to desipramine.
Topics: Adult; Depressive Disorder; Desipramine; Female; Fluoxetine; Humans; Metabolic Clearance Rate; Middl | 1992 |
Current status of tricyclic antidepressants in psychiatry: their pharmacology and clinical applications.
Topics: Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Cocaine; Depressive Disorder; Feeding and | 1991 |
Extrapyramidal symptoms upon discontinuation of fluoxetine.
Topics: Adult; Basal Ganglia Diseases; Depressive Disorder; Dystonia; Fluoxetine; Humans; Male; Substance Wi | 1991 |
Fluoxetine and neuroleptic synergistic effects.
Topics: Adolescent; Chlorpromazine; Diseases in Twins; Drug Synergism; Fluoxetine; Haloperidol; Humans; Male | 1991 |
Modification of quasi-morphine withdrawal with serotonin agonists and antagonists: evidence for a role of serotonin in the expression of opiate withdrawal.
Topics: 1-Methyl-3-isobutylxanthine; 5-Hydroxytryptophan; Animals; Fluoxetine; Male; Methysergide; Mianserin | 1989 |
Danger of MAOI therapy after fluoxetine withdrawal.
Topics: Adult; Drug Administration Schedule; Drug Interactions; Female; Fluoxetine; Humans; Substance Withdr | 1988 |
Danger of MAOI therapy after fluoxetine withdrawal.
Topics: Animals; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Monoamine Oxidase Inhibit | 1988 |